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Objectives: To determine trends, seasonality and the association between community antibiotic use and anti-
microbial resistance (AMR) in Escherichia coli and Klebsiella pneumoniae in urinary tract infections.
Methods: We analysed Dutch national databases from January 2008 to December 2016 regarding antibiotic
use and AMR for nitrofurantoin, trimethoprim, fosfomycin and ciprofloxacin. Antibiotic use was expressed as
DDD/1000 inhabitant-days (DID) and AMR was expressed as the percentage of resistance from total tested iso-
lates. Temporal trends and seasonality were analysed with autoregressive integrated moving average (ARIMA)
models. Each antibiotic use–resistance combination was cross-correlated with a linear regression of the ARIMA
residuals.
Results: The trends of DID increased for ciprofloxacin, fosfomycin and nitrofurantoin, but decreased for tri-
methoprim. Similar trends were found in E. coli and K. pneumoniae resistance to the same antibiotics, except for
K. pneumoniae resistance to ciprofloxacin, which decreased. Resistance levels peaked in winter/spring, whereas
antibiotic use peaked in summer/autumn. In univariate analysis, the strongest and most significant cross-
correlations were approximately 0.20, and had a time delay of 3–6 months between changes in antibiotic use
and changes in resistance. In multivariate analysis, significant effects of nitrofurantoin use and ciprofloxacin use
on resistance to these antibiotics were found in E. coli and K. pneumoniae, respectively. There was a significant
association of nitrofurantoin use with trimethoprim resistance in K. pneumoniae after adjusting for trimethoprim
use.
Conclusions: We found a relatively low use of antibiotics and resistance levels over a 9 year period. Although the
correlations were weak, variations in antibiotic use for these four antibiotics were associated with subsequent
variations in AMR in urinary pathogens.
Introduction
Urinary tract infections (UTIs) are the most frequent bacterial in-
fection in primary care, affecting 150 million people per year
worldwide.1,2 Women have higher risk of developing UTIs, and
60% of this group have at least one episode during their lifetime.1,2
Approximately 60%–80% of these infections are caused by
Escherichia coli and 3%–10% by Klebsiella pneumoniae.3–5
Currently, increasing antimicrobial resistance (AMR) in these urin-
ary bacteria has led to treatment failures and has increased the
societal cost to USD 3.5 billion per year in the USA alone.1
Antibiotic use is the key driver of AMR, and this association
implies a dynamic process in which a time delay between antibiot-
ic use and AMR may be involved.6–8 Some studies have considered
the influence of time on this association. For instance, a time delay
of 1–3 months between ceftazidime use and imipenem use and
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resistance to these antibiotics by Gram-negative bacteria was
reported in Spain.6 A similar time delay was found in the USA be-
tween high prescriptions of macrolides, b-lactams, fluoroquino-
lones and resistance in E. coli,8 while a delay of 1–2 months
between use of amoxicillin and resistance in urinary E. coli was
observed in Australia.7
Seasonality of antibiotic use in outpatients has been observed
in Europe and in the USA, where the highest consumption of antibi-
otics occurs in winter and spring compared with summer and au-
tumn.9–11 In high-consuming countries such as Greece, stronger
seasonal fluctuations were observed than in low-consuming coun-
tries such as the Netherlands.11 Strong seasonal fluctuations can
induce rapid selective pressure and further selection of antibiotic
resistance with short time delays.8 However, it has not been
elucidated what the time delay is between antibiotic use and
resistance in low-consuming countries with weak seasonal varia-
tions. Therefore, we aimed to determine trends, seasonality and
the time delay between antibiotic use and AMR in two clinically im-
portant urinary bacteria, E. coli and K. pneumoniae. We studied this
using time-series analysis in Dutch national databases for a period
of 9 years, which, unlike statistical methods that are commonly
applied in medical research, such as cross-sectional methods
and methods for repeated measurements, allowed us to take into
account trends and seasonality in the time series as well as pos-





Outpatient antibiotic prescriptions from January 2008 to December 2016
were obtained from the Dutch Foundation for Pharmaceutical Statistics
(SFK) database, which includes dispensing data of antibiotics from GPs, out-
patient clinics and dentists.12 Since 1990, SFK routinely collects data from
more than 95% of community pharmacies serving around 15.8 million peo-
ple, corresponding to 93% of the total Dutch population, and extrapolates
the data to 100% of antibiotic prescriptions in the Netherlands.12,13
Antibiotic use data were expressed in DDD for each Anatomical
Therapeutic Chemical (ATC) code at the fifth level. For this study, we ana-
lysed antibiotics mostly used in primary care to treat UTIs. According to the
current guidelines of the Dutch College of General Practitioners (NHG), nitro-
furantoin (ATC code J01XE01), fosfomycin (J01XX01) and trimethoprim
(J01EA01) should be used as first, second and third-choice therapy options,
respectively, for uncomplicated UTIs, and ciprofloxacin (J01MA02) as first-
choice option for UTIs with tissue invasion.14 We calculated the monthly
DDD per 1000 inhabitant-days (DID) of these antibiotics according to the
WHO ATC/DDD toolkit.15
Antimicrobial resistance
The Dutch national AMR surveillance system, named the Infectious
Diseases Surveillance Information System for Antimicrobial Resistance
(ISIS-AR), provided AMR data on E. coli and K. pneumoniae isolated from
urine samples. The ISIS-AR surveillance system is a combined initiative of
the Ministry of Health, Welfare and Sport and the Dutch Society of Medical
Microbiology (NVMM), and is coordinated by the Centre for Infectious
Disease Control (CIb) at the National Institute for Public Health and the
Environment (RIVM) in Bilthoven.16 Currently, ISIS-AR contains data from
routine antimicrobial susceptibility testing in 46 laboratories distributed
across the country serving hospitals, GPs, obstetrician practices, long-term
care facilities and public health facilities.16 The geographical distribution of
laboratories is representative of the Netherlands.12,16 Previously, the major-
ity of laboratories based their antimicrobial susceptibility testing on the CLSI
criteria, but between 2011 and 2013 most laboratories adapted their meth-
ods to EUCAST criteria.16 For reporting, such as the yearly NethMap report
on surveillance and use of antibiotics in the Netherlands by the Dutch
Working Group on Antibiotic Policy (SWAB) and the CIb, all MIC data are
reinterpreted using 2017 EUCAST criteria whenever possible.12
To exclude bias in determining trends, we included data from the 24 out
of 40 laboratories that continuously provided information to ISIS-AR from
2008 to 2016. Data included isolates from all 12 provinces of the
Netherlands. Resistance data included isolates selected under the following
conditions: (i) only urinary samples from GPs; (ii) the first isolate per patient
per year; and (iii) only data from laboratories that tested at least 50% of iso-
lates for that specific antibiotic, for each pathogen–agent combination.12
We calculated monthly resistance levels, and their binomial proportion
95% CIs, per year per antibiotic for E. coli and K. pneumoniae based on ISIS-
AR and NethMap methodology.12,16 Nitrofurantoin resistance levels were
not calculated for K. pneumoniae due to the lack of a susceptibility break-
point. For E. coli and K. pneumoniae, fosfomycin resistance data in 2008




R software 3.5.0 and RStudio version 1.0.153 were used for all analyses,
notably the packages ‘tseries’, ‘forecast’, ‘asta’ and ‘ggplot2’. In total we
created 11 time series on a monthly basis, four for each antibiotic use
expressed in DID, four for the percentage of resistance in E. coli and three
for the percentage of resistance in K. pneumoniae. We analysed each time
series with the methodology proposed by Box and Jenkins in 1976,17 based
on a three-stage modelling approach: (i) model identification; (ii) parameter
estimation; and (iii) model diagnostics.
This methodology is explained in more detail in the Supplementary
data (available at JAC Online). Briefly, we applied a decomposition proced-
ure using an additive model with the moving average method (LOESS) to
estimate trends, seasonal variation and irregularity from each time series.
Stationarity of time series was reached by first-order differencing, followed
by seasonal differencing, if a strong seasonality was observed. The autocor-
relation structure within each time series was analysed to select the terms
for an initial autoregressive integrated moving average (ARIMA) model.
ARIMA models were fitted for each time series and residuals were checked
for deviations from white noise.17,18
Cross-correlation analysis
To determine whether there was an association between resistance and
antibiotic use, analyses were done in pairs comparing each resistance level
with its corresponding antibiotic use. Cross-correlation analysis included
the following steps:8,19,20 (i) the coefficients of the cross-correlation func-
tion (CCF), with lags ranging from #12 to 12 months, were calculated with
the residuals of the fitted ARIMA models with antibiotic use as independent
variable and the corresponding resistance level as dependent variable; (ii)
inspection of the autocorrelogram (ACF) plot to identify at what lags the
correlation between the two series is the strongest [i.e. the cross-
correlation coefficient (CXY) peaking outside the 95% significance bounda-
ries]; and (iii) construction of multiple linear regression models with lagged
effects, seven in total, four for E. coli and three for K. pneumoniae.
Cross-correlation modelling allows the identification of associations be-
tween time series in both directions, i.e. positive and negative lags. The in-
terpretation of the CXY was as follows: a peak at a zero lag represents an
immediate response of resistance to antibiotic use. A significant peak at a
positive lag indicates that a change in antibiotic use would likely lag behind
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(i.e. occur after) a change in resistance, so that antibiotic use would be con-
sidered a lagging variable. A significant peak at a negative lag indicates that
a change in antibiotic use is followed by a change in resistance, so that anti-
biotic use would be considered a leading variable and a predictor of anti-
biotic resistance.
In the multiple linear regression analyses, residual values of the fitted
ARIMA models for the resistance time series were considered as the de-
pendent variables and the independent variables were the lagged residual
values of antibiotic use. The negative lag lengths of 1, 3, 6 and 12 months
were pre-selected to cover the short-term and long-term relationship be-
tween variables. The joint significance of these four lag lengths was tested
using F tests. In addition, we performed an extra analysis to determine the
influence of use of the analysed antibiotics on resistance to other antibiot-
ics, specifically between trimethoprim and nitrofurantoin, for which an as-
sociation has been found.21,22 These extra analyses consisted of multiple
linear regression analyses of trimethoprim and nitrofurantoin resistance
with simultaneous adjustment for trimethoprim and nitrofurantoin use,
using the same lag lengths as in the other regression analyses. The autocor-
relation structure of residuals of the linear regression models was exam-
ined to check for deviations from white noise.19
Results
During the 9 year study period, E. coli was the most commonly
found bacterium in urine samples, with a total of 487088 isolates
(Table 1). Resistance to trimethoprim was common in both
E. coli and K. pneumoniae (>20% prevalence of resistance).
Nitrofurantoin was the most prescribed antibiotic (1.32 DID) fol-
lowed by ciprofloxacin (0.54 DID) (Table 2).
Trends of outpatient antibiotic use and resistance levels
Temporal trends and changes in antibiotic use and resistance lev-
els in urinary bacteria over the study period are presented in
Figure 1 and Table 3. The use of fosfomycin increased from
0.01 DID in 2009 to 0.05 DID in 2016 (an increase of 400%), and
the use of nitrofurantoin increased from 1.12 in 2008 to 1.41 in
2016 (a total increase of 25.9%). The use of trimethoprim showed
a steady decreasing trend from 0.21 DID in 2008 to 0.15 DID in
2016 (a total decrease of 33.3%). The use of ciprofloxacin was vari-
able, showing an increasing trend from 0.47 DID in 2008 to
0.61 DID in 2015, followed by a decrease until the end of 2016 (a
total increase of 29.8%).
Fosfomycin resistance showed a steady increase from 0.6% in
2009 to 1.4% in 2016 in E. coli (a total increase of 133.3%), and
from 16.2% to 32.6% for K. pneumoniae (a total increase of
101.2%). Also, nitrofurantoin resistance in E. coli showed an
increasing trend between 2008 (1.8%) and 2014 (2.5%), followed
by a decrease from 2015 onwards (a total increase of 5.6%).
Furthermore, the prevalence of resistance to trimethoprim showed
a slowly decreasing trend from 27.4% in 2008 to 24.8% in 2016 in
E. coli (a decrease of 9.5%) and from 29.0% to 22.3% in K. pneumo-
niae (a total decrease of 23.1%). Ciprofloxacin resistance in K.
pneumoniae showed a decreasing trend from 12.0% in 2008 to
9.9% in 2016 (a total decrease of 17.5%). In E. coli, ciprofloxacin re-
sistance initially increased from 9.6% in 2008 to 10.5% in 2012, fol-
lowed by a decrease from 10.4% in 2011 to 9.9% in 2016 (a total
increase of 3.1%).
Seasonality of outpatient antibiotic use and resistance
levels
We identified weak seasonal variation in both antibiotic use, peak-
ing in summer/autumn, and resistance levels, peaking in winter/
spring (Figures 2 and 3). Seasonal variation in E. coli was more pro-
nounced for nitrofurantoin use than for other antibiotics, with use
approximately 0.10 DID higher in summer/autumn. Seasonal vari-
ation of resistance levels in E. coli was more pronounced for tri-
methoprim, which was 1 percentage point higher in winter/spring,
and ciprofloxacin, which was 0.6 percentage points higher in the
same seasons. In K. pneumoniae, seasonal variation of resistance
levels was more pronounced for fosfomycin: 2 percentage points
higher in winter. For more detail see Tables S1–S3.
Association between outpatient antibiotic use and
resistance levels
The final specification of the fitted ARIMA models is presented in
Table S4. In general, we found weak associations between anti-
biotic use and resistance (Tables 3 and 4).
Cross-correlation analysis
Cross-correlation coefficients (based on univariate analysis) are
shown in Figure 4 and significant coefficients are presented in
Table 4. The highest cross-correlations were approximately 0.20
with a time delay (lag length) of 3–6 months. In E. coli combina-
tions, significant negative and positive correlations at zero lag
were observed for ciprofloxacin (CXY=#0.23, P = 0.02), fosfomycin
(CXY= 0.22, P = 0.03) and trimethoprim (CXY=#0.22, P = 0.02)
Table 1. Summary data on antibiotic resistance in the Netherlands from
January 2008 to December 2016
Number of isolates tested Proportion of
isolates
resistant (%)
and 95% CIBacteria/antibiotic total resistant
E. coli
Ciprofloxacin 484993 49207 10.2 (10.1–10.2)
Nitrofurantoin 487088 10242 2.1 (2.1–2.1)
Trimethoprim 482030 129032 26.8 (26.6–26.9)
Fosfomycin 328625 3393 1.0 (1.0–1.07)
K. pneumoniae
Ciprofloxacin 50944 5360 10.5 (10.3–10.8)
Trimethoprim 50639 12568 24.8 (24.4–25.1)
Fosfomycin 34424 9602 27.9 (27.4–28.4)
Table 2. Summary data on antibiotic use in the Netherlands from
January 2008 to December 2016
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(Table 4). Peaks at negative lags were found for nitrofurantoin and
trimethoprim, suggesting that an increase in nitrofurantoin use
was followed by an increase in resistance with a time delay of
6 months (CXY = 0.22, P = 0.02). A decrease in trimethoprim use was
followed by a decrease in resistance with a time delay of 3 months
(CXY = 0.22, P = 0.03). Furthermore, peaks at positive lags were
found for fosfomycin, ciprofloxacin and trimethoprim, which repre-
sents the counterintuitive result that if resistance to fosfomycin,
ciprofloxacin or trimethoprim rises, the use of these antibiotics will
increase 6, 7 or 8 months later, respectively (Figure 4 and Table 4).
In K. pneumoniae combinations, significant associations at
negative lags were found for ciprofloxacin and trimethoprim,
whereas for fosfomycin an association was identified at a positive
lag of 10 months. A decrease in trimethoprim use was followed by
a decrease in resistance with a time delay of 2 months (CXY= 0.24,
P = 0.01) and 5 months (CXY= 0.21, P = 0.03). An increase in cipro-
floxacin use was followed by a decrease of resistance with a time
delay of 6 months (CXY= 0.28, P = 0.004) (Figure 4 and Table 4).
Multiple linear regression analyses of antibiotic use on
antibiotic resistance
In multivariate analysis using linear regression, which was per-
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Figure 1. Trends of outpatient antibiotic use and antimicrobial resistance levels in E. coli and K. pneumoniae in the Netherlands from January 2008 to
December 2016. Antibiotic use was expressed as DID and resistance levels as percentages. Smoothed trends (black solid line) and their 95% CIs (grey
shading around the line) were estimated by seasonal and trend decomposition using local regressions (LOESS). Grey lines show the original time ser-
ies. Fosfomycin resistance is presented from 2009 to 2018. No susceptibility breakpoint was available for nitrofurantoin in K. pneumoniae isolates.
Antibiotic use data source: SFK. Resistance data source: ISIS-AR in the Netherlands.
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the lagged effect of antibiotic use on resistance was only statistic-
ally significant for nitrofurantoin (F = 2.52, P = 0.05) in E. coli combi-
nations and for ciprofloxacin (F = 3.86, P = 0.01) in K. pneumoniae
combinations. In a separate analysis, significant co-resistance was
found for nitrofurantoin use, showing that nitrofurantoin use pre-
dicts changes in resistance to trimethoprim in K. pneumoniae after
adjustment for lagged trimethoprim use (F = 4.56, P = 0.002)
(Table 5). We did not find significant co-resistance for the other
analysed antibiotics.
Discussion
In Dutch databases covering a 9 year period, we found a relatively
low use of antibiotics and relatively low resistance levels compared
with southern European countries. Antibiotic use and resistance
levels showed weak seasonal variations peaking in summer/au-
tumn and winter/spring, respectively. We show that the use of
nitrofurantoin, fosfomycin and ciprofloxacin increased over time,
and so did resistance levels to these antibiotics. Conversely, tri-
methoprim use decreased and so did trimethoprim resistance. Use
of nitrofurantoin was associated with a decrease in trimethoprim
resistance in K. pneumoniae, at several lag lengths.
In contrast with previous studies, the evidence for an associ-
ation between antibiotic use and resistance was the strongest,
with a time delay of 3–6 months, probably due to low levels of anti-
biotic use in the Netherlands. Studies done in the USA, Australia
and England have shown strong associations between high resist-
ance levels in E. coli and high antibiotic use during winter, with a
time delay of 1–2 months.7,8,23 These associations were mainly
found among antibiotics often prescribed for respiratory infections,
such as b-lactams, macrolides and fluoroquinolones.7,8,23 These
antibiotics account for more than 40% of total antibiotic consump-
tion in the USA and Europe, and their usage increases by a range of
24%–30% in winter.8,10,11,24 In the Netherlands, a weak winter
seasonal variation of overall outpatient antibiotic use was
described.11,24 This was considered to be a result of a consistent
low antibiotic consumption (mean of 10.2 DID) compared with
high-consuming countries such as France (mean of 33.0 DID) and
Belgium (mean of 25.4 DID). Similar to the findings of our study,
weak seasonal differences among antibiotics used to treat
UTIs were shown in England,25 suggesting that the observed weak
seasonal summer and autumn variation in antibiotic use could
be influenced by the summer seasonality of the incidence of
UTIs.26–29
We found that the association between nitrofurantoin use and
resistance in E. coli was with a delay of 3 and 6 months. Similar
results were found in a 4 year study in England, in which nitrofur-
antoin resistance lagged behind nitrofurantoin use at 6 months.23
These results could be explained by studies showing that once the
selective pressure is removed, the wild type of E. coli replaced
nitrofurantoin-resistant strains due to the high fitness cost of
resistance.30 Nitrofurantoin has a multifactorial mechanism of ac-
tion with activity against enzymes that damage vital processes
in the bacterium,31 and nitrofurantoin resistance genes are not
often located on mobile genetic elements in bacteria.30 In the
Netherlands, nitrofurantoin is the first-choice therapy for uncom-
plicated UTIs and thus highly prescribed,14 but AMR was not shown
to increase at high rates.12,16
The cross-correlation coefficients found in this study were rela-
tively low (all approximately 0.20 or smaller), similar to those
found in a previous study.8 This suggests that the contribution of
antibiotic use to the dynamic of resistance in a low-consuming
country like the Netherlands is small, meaning that other factors
play an important role. Previous studies have found that patient-
related factors such age, sex and nutritional habits were associ-
ated with resistance to ciprofloxacin in urinary E. coli isolates.32,33
In addition, other factors, such as international travel, the spread
Table 3. Relative change in outpatient antibiotic use and resistance levels in E. coli and K. pneumoniae during the period between January 2008 and
December 2016 in the Netherlands
Antibiotic
Study period
Relative change (%)a2008 2009 2010 2011 2012 2013 2014 2015 2016
Mean outpatient antibiotic use (DID)
ciprofloxacin 0.47 0.48 0.51 0.51 0.52 0.54 0.6 0.61 0.61 29.8
nitrofurantoin 1.12 1.18 1.23 1.31 1.38 1.39 1.41 1.42 1.41 25.9
trimethoprim 0.21 0.21 0.20 0.20 0.19 0.17 0.16 0.15 0.14 #33.3
fosfomycin 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.04 0.05 400.0
Mean resistance level in E. coli (%)
ciprofloxacin 9.6 9.9 10.4 10.4 10.5 10.4 10.1 10 9.9 3.1
nitrofurantoin 1.8 1.9 1.8 2.0 2.3 2.4 2.5 2.2 1.9 5.6
trimethoprim 27.4 28.7 28 27.5 27.6 26.8 24.6 25.5 24.8 #9.5
fosfomycin NA 0.6 0.8 0.9 0.9 0.9 1.1 1.3 1.4 133.3
Mean resistance level in K. pneumoniae (%)
ciprofloxacin 12 11.3 11 11.1 10.5 9.9 10.3 9.8 9.9 #17.5
trimethoprim 29 28.2 30.2 26.9 25.3 23.0 21.7 21.5 22.3 #23.1
fosfomycin NA 16.2 21 22.3 25.6 29.9 30.9 32.3 32.6 101.2
NA, not analysed.
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of resistance genes in the community34,35 and the interaction with
the use of other antibiotics,6 were found to be actively participating
in the dynamic of resistance selection.
Moreover, it has been shown that having received two previous
prescriptions of trimethoprim and ciprofloxacin increased the risk
of resistance to these antibiotics in urinary E. coli.33 In our study,
the use of ciprofloxacin alone would explain about 11% of the
resistance variation in urinary bacteria. It may be that use of
other fluoroquinolones or use of b-lactams to treat respiratory
infections contributes to the temporal changes in ciprofloxacin
resistance. One study found an association between use of
other fluoroquinolones and ciprofloxacin resistance in E. coli
with a delay of 1 month,8 while another study showed that
levofloxacin use in the community was associated with
ciprofloxacin-resistant E. coli in hospitals with a time delay of
12 months.36 Resistance mechanisms to antibiotics differ
between bacteria; unlike nitrofurantoin resistance, the levels of
ciprofloxacin resistance can easily increase due to its multifac-
torial selection mechanism (e.g. target-site mutation, efflux
pumps, and transmissible resistance on mobile genetic ele-
ments) and the demonstrated fitness advantage of resistant
strains over susceptible strains.37
The latter could explain the significant immediate effect of
ciprofloxacin use on resistance in E. coli found in this study.
Interestingly, a study in England found an association between
amoxicillin use and the increase of amoxicillin and ciprofloxacin re-
sistance in urinary E. coli.38 Therefore, the possible co-resistance
needs further investigation to understand its influence on changes
in trends and the lagged AMR development.
Furthermore, the strongest association between the decrease
in trimethoprim use and resistance in urinary bacteria was with a
delay of 2–5 months. The decrease in trimethoprim resistance
could partly be explained by the decreased use of trimethoprim/
sulfamethoxazole and increased nitrofurantoin use. In the USA
and Spain, a significant association of approximately 20% between
trimethoprim/sulfamethoxazole use and trimethoprim resistance
in E. coli was found, with a time delay of 3–7 months.8,20
Interestingly, in England and the Netherlands, an association with
reduced trimethoprim resistance in urinary E. coli was shown for
nitrofurantoin use.21,22,38 Similarly, we found that an increase in
nitrofurantoin use was associated with a decrease in trimethoprim
resistance in K. pneumoniae. Possibly, nitrofurantoin use selects for
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Figure 2. Seasonal variations of outpatient antibiotic use and resistance levels in Escherichia coli from 2008 to 2016 in the Netherlands. Seasonal var-
iations were calculated by a decomposition procedure using an additive model with the moving average method. The y-axis refers to the monthly
change around the mean (horizontal solid line) in the percentage of resistance levels and in antibiotic use expressed as DID. Antibiotic use data
source: SFK; Resistance data source: ISIS-AR in the Netherlands.
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The temporal changes in fosfomycin resistance could not be
explained by the lagged fosfomycin use, despite its dramatic in-
crease of 400% from 2009 to 2016. The increase in fosfomycin use
is possibly due to the update to the NHG guidelines in 2013, in which
fosfomycin instead of trimethoprim was recommended as second-
choice therapy for uncomplicated UTIs.14 In vitro studies suggest
that fosfomycin use is associated with rapid selection of resistance
in Enterobacteriaceae,39,40 which could explain the immediate se-
lection response in E. coli found in this study. In Spain, the rapid in-
crease in fosfomycin use in the community was found to be a risk
factor for fosfomycin resistance in ESBL E. coli,41 and it was associ-
ated with a 24.5% increase in fosfomycin resistance in E. coli with a
time delay of 10 months.20 Future studies are necessary to confirm
this association in different multinational settings, in which patterns
of antibiotic use may differ from those in the Netherlands.
Our study has substantial strengths, but also some limitations.
This is the first outpatient-based study assessing trends, seasonal-
ity and the association between resistance in urinary bacteria and
antibiotic use in a low-consuming country. The type of analysis
applied, the construction of time series with short time intervals
(i.e. months) over 9 years, and the unbiased collection of the infor-
mation regarding antibiotic use and resistance are also substantial
strengths of this study. One possible limitation is the high level of
aggregation of our study (i.e. national level), which can lead to a
lower power for the analysis than a lower level of aggregation (e.g.
provinces, municipalities) would provide. However, similar studies
in other countries at the same level of aggregation found strong
and significant correlations.8,20 Moreover, selection bias is possible
since Dutch GPs usually do not send urine samples for identifica-
tion and susceptibility testing except in complicated UTI cases or
if antibiotic treatment failure is suspected.12 Therefore, resistance
levels may be overestimated; however, resistance levels were
found to be similar amongst unselected urinary cultures from un-
complicated UTI in general practice in the Netherlands.5 A final
limitation may be the ecological nature of this study; we could not
rule out a fallacy in our results since the analysis did not control for
patient-related factors. Patient demographic data were only
available for antibiotic resistance, limiting the value of trying to
include variables such as age, sex and location in our analysis.
However, given the large sample size, effects of sampling variation
in patient-level characteristics should theoretically be negligible.
Moreover, the trends of antibiotic use were found to be similar
among age and sex categories.42 Similar figures have been found
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Figure 3. Seasonal variations of outpatient antibiotic use and resistance levels in Klebsiella pneumoniae from 2008 to 2016 in the Netherlands.
Seasonal variations were calculated by a decomposition procedure using an additive model with the moving average method. The y-axis refers to
the monthly change around the mean (horizontal solid line) in the percentage of resistance levels and in antibiotic use expressed in DID. Antibiotic
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In conclusion, in a low-consuming country like the Netherlands
there was a weak association between antibiotic use and resist-
ance, and the strongest evidence for this association was observed
with a time delay of 3–6 months between changes in antibiotic use
and changes in resistance.
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Table 4. Cross-correlation and multiple linear regression results with lagged effects between antimicrobial resistance in E. coli and K. pneumoniae
and antibiotics used to treat urinary tract infections in the Netherlands
Bacteria ABUa
Cross-correlation Multiple linear regression for lagged ABU
lag




(months)d coef. 95% CI P value
E. coli CIP 0 #0.23 0.02 6.6 1.39 0.25 CIP1 0.08 #0.27 to 0.42 0.65
!7 0.21 0.03 CIP3 0.08 #0.26 to 0.43 0.64
CIP6 0.16 #0.18 to 0.51 0.34
CIP12 #0.32 #0.67 to 0.03 0.07
E. coli FOS 0 0.22 0.03 2.5 0.42 0.79 FOS1 0.21 #1.36 to 1.79 0.79
!6 0.20 0.04 FOS3 0.36 #1.26 to 1.97 0.66
FOS6 #0.98 #2.59 to 0.62 0.23
FOS12 #0.20 #1.85 to 1.44 0.80
E. coli NIT #6 0.22 0.02 11.3 2.52 0.05 NIT1 #0.48 #1.47 to 0.50 0.33
NIT3 1.23 0.19 to 2.28 0.02
NIT6 0.98 #0.02 to 1.98 0.05
NIT12 #0.47 #1.56 to 0.62 0.39
E. coli TMP 0 #0.22 0.02 5.7 1.19 0.32 TMP1 #0.02 #0.18 to #0.14 0.80
#3 0.22 0.02 TMP3 0.15 #0.01 to 0.32 0.07
!8 0.22 0.02 TMP6 0.10 #0.06 to 0.26 0.23
TMP12 0.00 #0.17 to 0.17 0.99
K. pneumoniae CIP #6 0.28 0.004 16.3 3.86 0.01 CIP1 0.04 #0.75 to 0.82 0.93
CIP3 0.56 #0.23 to 1.34 0.16
CIP6 1.45 0.67 to 2.22 <0.001
CIP12 0.36 #0.43 to 1.16 0.37
K. pneumoniae FOS !10 0.28 0.01 3.7 0.64 0.64 FOS1 0.04 #0.50 to 0.59 0.87
FOS3 0.32 #0.24 to 0.88 0.26
FOS6 #0.25 #0.81 to 0.30 0.37
FOS12 #0.29 #0.85 to 0.28 0.32
K. pneumoniae TMP #2 0.24 0.01 5.6 1.17 0.33 TMP1 #0.01 #0.50 to 0.49 0.98
#5 0.21 0.03 TMP3 #0.20 #0.71 to 0.31 0.45
TMP6 0.48 #0.01 to 0.97 0.06
TMP12 0.22 #0.29 to 0.74 0.39
ABU, antibiotic use; coef., coefficient; F, F test statistic; CIP, ciprofloxacin; NIT, nitrofurantoin; TMP, trimethoprim; FOS, fosfomycin.
aCombination of antimicrobial resistance and antibiotic use for E. coli and K. pneumoniae.
bMonths of lag in which significant peaks were observed in the cross-correlation function plot. For the cross-correlation function, ! and # signs show
significant positive and negative lag lengths.
cThe F-test assesses whether there is any association between lagged antibiotic use and the antimicrobial resistance level, for lags of 1, 3, 6 and
12 months combined.
dLag length in months of antibiotic use in the linear regression models with lagged effects. The length was chosen to cover the short-term and long-
term relationship between variables. The (negative) lag lengths of 1, 3, 6 and 12 months were pre-selected, irrespective of the P values. Lagged re-
gression models used as dependent variables the residuals of ARIMA models for resistance time series, and as independent variables the lagged
residuals from ARIMA models for antibiotic use time series.
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Figure 4. CCF of combinations between antibiotic use and resistance levels in E. coli and K. pneumoniae. The CCF represents lag lengths from
#12 months (leading effect of antibiotic use) to 12 months (lagging effect of antibiotic use). The horizontal dotted lines show the cross-correlation
significance limit at 95%. Vertical solid lines shown cross-correlation coefficients between the two time series. Cross-correlation peaks outside the
limits are considered significant, thus a peak at negative or positive lag is statistically significant and shows that antibiotic use is associated with re-
sistance. A negative lag implies that a change in antibiotic use is followed by a change in resistance (predictor variable), and a positive lag implies
that a change in antibiotic use would likely occur after a change in resistance (lagging variable). The 95% CIs are not adjusted for multiple testing.
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Table 5. Results of multiple linear regression with lagged effects for co-resistance between AMR in E. coli and K. pneumoniae and two antibiotics
used to treat urinary tract infections in the Netherlands
Bacteria AMR
Multiple linear regression for lagged ABU
R2 (%) F P value (F-test)a ABU lag (months)b coef. 95% CI P value
E. coli NIT 16.3 2.52 0.08 NIT1 0.02 #1.42 to 1.45 0.98
NIT3 1.51 0.12–2.89 0.03
NIT6 0.92 #0.49 to 2.33 0.20
NIT12 #1.33 #2.82 to 0.16 0.08
1.11 0.36 TMP1 #0.5 #1.35 to 0.35 0.24
TMP3 #0.25 #1.09 to 0.58 0.55
TIMP6 #0.03 #0.86 to 0.80 0.94
TMP12 0.74 #0.11 to 1.59 0.09
E. coli TMP 8.0 0.81 0.59 TMP1 0.03 #0.21 to 0.26 0.81
TMP3 0.12 #0.11 to 0.35 0.29
TIMP6 0.06 #0.17 to 0.29 0.59
TMP12 #0.11 #0.34 to 0.37 0.37
0.47 0.76 NIT1 #0.08 #0.47 to 0.32 0.71
NIT3 0.02 #0.37 to 0.40 0.94
NIT6 0.08 #0.31 to 0.47 0.69
NIT12 0.27 #0.15 to 0.68 0.20
K. pneumoniae TMP 24.1 2.97 0.01 TMP1 #0.43 #1.09 to 0.23 0.19
TMP3 0.23 #0.43 to 0.88 0.49
TMP6 0.68 0.04 to 1.33 0.04
TMP12 #0.15 #0.81 to 0.51 0.65
4.56 0.002 NIT1 1.21 0.09–2.32 0.03
NIT3 #1.26 #2.34 to #0.18 0.02
NIT6 #0.76 #1.85 to 0.34 0.17
NIT12 1.34 0.18–2.49 0.02
ABU, antibiotic use; coef., coefficient; F, F test statistic; CIP, ciprofloxacin; NIT, nitrofurantoin; TMP, trimethoprim; FOS, fosfomycin.
aThe F-test assesses whether there is any association between a lagged antibiotic use and the antimicrobial resistance level, for lags of 1, 3, 6 and
12 months, to each antibiotic combined.
bLag length in months of antibiotic use used in the linear regression models with lagged effects. The length was chosen to cover the short-term and
long-term relationship between variables. The (negative) lag lengths of 1, 3, 6 and 12 months were pre-selected, irrespective of the P values. Lagged
regression models used as dependent variables the residuals of ARIMA models for resistance time-series, and as independent variables the lagged
residuals from ARIMA models for antibiotic use time series.
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